Bruno Spinosa De Martinis

Bruno Spinosa De Martinis

Auto-generated profile, based on publicly available information

Bruno Spinosa De Martinis

Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2011 in Neuropsychopharmacology
Verified
Journal Article
Closed access
MBMateus M Bergamaschi
Mateus M Bergamaschi
RQRegina Helena Costa Queiroz
Regina Helena Costa Queiroz
MCMarcos Hortes Nisihara Chagas
Marcos Hortes Nisihara Chagas
DODanielle Chaves Gomes de Oliveira
Danielle Chaves Gomes de Oliveira
BMBruno Spinosa De Martinis
Bruno Spinosa De Martinis
JCJOSE A DE S de Souza CRIPPA
JOSE A DE S de Souza CRIPPA

16 September 2011 in Human Brain Mapping
Verified
Journal Article
Closed access
DADraulio B. de Araujo
Draulio B. de Araujo
SRSidarta Ribeiro
Sidarta Ribeiro
GCGuillermo A. Cecchi
Guillermo A. Cecchi
FCFabiana M. Carvalho
Fabiana M. Carvalho
TSTiago A. Sanchez
Tiago A. Sanchez
ASAntonio C. Santos
Antonio C. Santos

19 August 2021 in Forensic Toxicology
Verified
Journal Article
Open access
PDF file
ECEduardo Geraldo de Campos
Eduardo Geraldo de Campos
BCBruno Ruiz Brandão da Costa
Bruno Ruiz Brandão da Costa
FSFabiana Spineti dos Santos
Fabiana Spineti dos Santos
FMFernanda Monedeiro
Fernanda Monedeiro
MAMarcela Nogueira Rabelo Alves
Marcela Nogueira Rabelo Alves
BMBruno Spinosa De Martinis
Bruno Spinosa De Martinis
Purpose: The use of alternative matrices in toxicological analyses has been on the rise in clinical and forensic settings. Specimens alternative to blood and urine are useful in providing additional information regarding drug exposure and analytical benefits. The goal of this paper is to present a critical review on the most recent literature regarding the application of six common alternative matrices, i.e., oral fluid, hair, sweat, meconium, breast milk and vitreous humor in forensic toxicology. Methods: The recent literature have been searched and reviewed for the characteristics, advantages and limitations of oral fluid, hair, sweat, meconium, breast milk and vitreous humor and its applications in the analysis of traditional drugs of abuse and novel psychoactive substances (NPS). Results: This paper outlines the properties of six biological matrices that have been used in forensic analyses, as alternatives to whole blood and urine specimens. Each of this matrix has benefits in regards to sampling, extraction, detection window, typical drug levels and other aspects. However, theses matrices have also limitations such as limited incorporation of drugs (according to physical–chemical properties), impossibility to correlate the concentrations for effects, low levels of xenobiotics and ultimately the need for more sensitive analysis. For more traditional drugs of abuse (e.g., cocaine and amphetamines), there are already data available on the detection in alternative matrices. However, data on the determination of emerging drugs such as the NPS in alternative biological matrices are more limited. Conclusions: Alternative biological fluids are important specimens in forensic toxicology. These matrices have been increasingly reported over the years, and this dynamic will probably continue in the future, especially considering their inherent advantages and the possibility to be used when blood or urine are unavailable. However, one should be aware that these matrices have limitations and particular properties, and the findings obtained from the analysis of these specimens may vary according to the type of matrix. As a potential perspective in forensic toxicology, the topic of alternative matrices will be continuously explored, especially emphasizing NPS.

25 February 2016 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
DBDayanne Cristiane Mozaner Bordin
Dayanne Cristiane Mozaner Bordin
MAMarcela Nogueira Rabelo Alves
Marcela Nogueira Rabelo Alves
ECEduardo Geraldo de Campos
Eduardo Geraldo de Campos
BMBruno Spinosa De Martinis
Bruno Spinosa De Martinis

1 August 2010 in Brain Research
Verified
Journal Article
Closed access
OCOmar J. Cassol-Jr
Omar J. Cassol-Jr
CCClarissa M. Comim
Clarissa M. Comim
BSBruno R. Silva
Bruno R. Silva
FHFernanda V. Hermani
Fernanda V. Hermani
LCLarissa S. Constantino
Larissa S. Constantino
FDFelipe Dal-Pizzol
Felipe Dal-Pizzol

17 March 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RSRaquel A. Do Val-Da Silva
Raquel A. Do Val-Da Silva
JPJose Eduardo Peixoto-Santos
Jose Eduardo Peixoto-Santos
LKLudmyla Kandratavicius
Ludmyla Kandratavicius
JRJana B. De Ross
Jana B. De Ross
IEIngrid Esteves
Ingrid Esteves
JLJoao Pereira Leite
Joao Pereira Leite
The present study reports the behavioral, electrophysiological, and neuropathological effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the intrahippocampal pilocarpine-induced status epilepticus (SE) rat model. CBD was administered before pilocarpine-induced SE (group SE+CBDp) or before and after SE (group SE+CBDt), and compared to rats submitted only to SE (SE group), CBD, or vehicle (VH group). Groups were evaluated during SE (behavioral and electrophysiological analysis), as well as at days one and three post-SE (exploratory activity, electrophysiological analysis, neuron density, and neuron degeneration). Compared to SE group, SE+CBD groups (SE+CBDp and SE+CBDt) had increased SE latency, diminished SE severity, increased contralateral after discharges latency and decreased relative powers in delta (0.5-4 Hz) and theta (4-10 Hz) bands. Only SE+CBDp had increased vertical exploratory activity one-day post SE and decreased contralateral relative power in delta three days after SE, when compared to SE group. SE+CBD groups also showed decreased neurodegeneration in the hilus and CA3, and higher neuron density in granule cell layer, hilus, CA3, and CA1, when compared to SE group. Our findings demonstrate anticonvulsant and neuroprotective effects of CBD preventive treatment in the intrahippocampal pilocarpine epilepsy model, either as single or multiple administrations, reinforcing the potential role of CBD in the treatment of epileptic disorders.